Join us at the externally-led JIA Patient-Focused Drug Development meeting
We are hosting, along with our partner, the Childhood Arthritis and Rheumatology Research Alliance (CARRA), the Juvenile Idiopathic Arthritis Patient-Focused Drug Development (PFDD) meeting. This meeting, driven by our patients and caregivers, will provide the U.S. Food and Drug Administration (FDA) and industry personnel with input directly from you on how this disease affects your life, your experiences with current treatments, and the need for newer and better treatments.
Continue reading Your Disease, Your Voice
The Arthritis Foundation is funding a new program to help support the Childhood Arthritis and Rheumatology Research Alliance (CARRA) and the CARRA Registry (registry). Eight sites were selected to receive funding to support the salary of a dedicated registry research coordinator for one year. Until now, some sites have been short-handed for this important research position.
Researchers collect information through studies on many pediatric patients with rheumatic diseases over time and store it in the registry. Research coordinators play a critical role in making sure research studies run smoothly. Those supported by this program will:
Continue reading Funding Juvenile Research Coordinators Across the County
Every family whose child receives a diagnosis of a rheumatic disease (such as juvenile idiopathic arthritis (JIA), lupus, dermatomyositis and scleroderma) wants the best treatment and care. The doctors who treat your child also want to provide the best treatment and care for their patients. Over the past 20 years, new discoveries and medicines have greatly improved the lives of children with rheumatic diseases. Many new treatment choices are good, but how can we know which medication will work the best for each child? What if we can learn the answer to this question by simply collecting information on how usual care and treatment work for a lot of children with the same disease?
Continue reading A New Way to Compare How Different Treatments Work for Patients with Pediatric Rheumatic Diseases